Pioglitazone and insulin
ApprovedSmall molecule
TakedaPioglitazone and insulin is one of 133 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.
4
Indications
13
Total Trials
0
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Pioglitazone and insulin
TakedaApproved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus7 trials
Show 4 more trials
Type 2 Diabetic Patients1 trial
Type 2 Diabetes1 trial
Cardiovascular Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pioglitazone and insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]